Shift in Rx From 2001 to 2020 for Disease-Modifying Therapy for Multiple Sclerosis

Oral disease-modifying therapies dominated new initiations by 2020 to 62.3%.

Related Keywords

New Jersey ,United States ,Rutgers University ,New Brunswick ,Mackenzie Henderson ,Healthday News ,